MCID: CTN003
MIFTS: 53

Cutaneous Lupus Erythematosus

Categories: Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Cutaneous Lupus Erythematosus

MalaCards integrated aliases for Cutaneous Lupus Erythematosus:

Name: Cutaneous Lupus Erythematosus 12 74 52 36 15 17
Lupus Erythematosus, Cutaneous 52 71
Lupus Erythematosus Cutaneous 54

Classifications:



External Ids:

Disease Ontology 12 DOID:0050169
KEGG 36 H01595
UMLS 71 C0024137

Summaries for Cutaneous Lupus Erythematosus

KEGG : 36 Cutaneous lupus erythematosus (CLE) is the skin-related form of lupus erythematosus (LE), with a broad spectrum of clinical manifestations and a variable course. CLE is a frequent finding in patients with systemic lupus erythematosus (SLE) and can also exist as a single entity without associated systemic autoimmunity (LE-specific skin disease). Despite ongoing research into the cause of CLE, it remains unclear how CLE relates to SLE pathogenesis. LE-specific skin disease includes the subtypes of CLE such as acute cutaneous LE (ACLE), subacute cutaneous LE (SCLE), chronic cutaneous LE (CCLE), and intermittent CLE (ICLE). ACLE is characterized by malar rash or maculopapular eruption on sun exposed areas. SCLE characteristically presents as annular or psoriasiform plaques in a photo distribution. CCLE can be further divided into discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain LE (CLE), and LE tumidus (LET). The pathogenesis of CLE is multifactorial and involves genetic predisposition, environmental triggers, and abnormalities in the immune response. It has been reported that many genetic risk factors for CLE involve HLA or interferon-related pathways. Corticosteroids and antimalarials were considered as the most suitable and effective systemic drugs for CLE patients.

MalaCards based summary : Cutaneous Lupus Erythematosus, also known as lupus erythematosus, cutaneous, is related to subacute cutaneous lupus erythematosus and alopecia, and has symptoms including pruritus and exanthema. An important gene associated with Cutaneous Lupus Erythematosus is CXCR3 (C-X-C Motif Chemokine Receptor 3), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs belimumab and Immunosuppressive Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and lung, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A lupus erythematosus that causes skin lesions on parts of the body that are exposed to sunlight.

Wikipedia : 74 Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes... more...

Related Diseases for Cutaneous Lupus Erythematosus

Diseases in the Cutaneous Lupus Erythematosus family:

Rare Cutaneous Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus

Diseases related to Cutaneous Lupus Erythematosus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 781)
# Related Disease Score Top Affiliating Genes
1 subacute cutaneous lupus erythematosus 35.0 TRIM21 TNF
2 alopecia 31.4 TNF KRT15 IL1B IFNG
3 erythema multiforme 31.1 TNF IL6 IFNG CXCR3
4 chilblain lupus 1 30.9 TREX1 IRF5 IFNA1
5 lupus erythematosus 30.9 TRIM21 TREX1 TNF RO60 MX1 IRF5
6 rosacea 30.7 TNF IL6 IL18
7 acute graft versus host disease 30.7 TNF IL18 IL10 IFNG
8 thyroiditis 30.7 TNF IL6 IL10 IFNA1
9 polyneuropathy 30.7 TNF IL6 IL1B CD40LG
10 pemphigus 30.6 TNF IL6 IL10 CD40LG
11 blepharitis 30.5 TNF IL6 IL1B
12 graft-versus-host disease 30.5 TNF IL6 IL1B IL10 IFNG
13 localized scleroderma 30.5 TNFSF13B TNF SELE IL6
14 actinic prurigo 30.5 TNF SELE IL1B
15 keratoconjunctivitis sicca 30.5 TRIM21 TNFSF13B TNF RO60
16 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.4 TNFSF13B IL17A IL10 IFNG
17 drug-induced lupus erythematosus 30.4 TNF IL6 IL1B IL17A IL10
18 urticaria 30.3 TNF SELE IL6 IL10 CD40LG
19 antiphospholipid syndrome 30.3 TNF SELE CD40LG
20 lymphadenitis 30.3 TNF IL1B IL18 IL10 IFNG CXCR3
21 herpes zoster 30.3 TNF IL10 IFNG IFNA1 CD40LG
22 exanthem 30.3 TRIM21 TNF IL6 IL1B IL10 IFNG
23 hepatitis b 30.2 TNF MX1 IL6 IFNG IFNA1
24 aspergillosis 30.1 TNF IL6 IL1B IL18 IL10 IFNG
25 acute pancreatitis 30.1 TNF IL6 IL1B IL18 IL10
26 lichen planus 30.1 TNF MX1 IL6 IL17A IL10 IFNG
27 nervous system disease 30.1 TNF IL6 IL1B IFNG CXCR3
28 chronic inflammatory demyelinating polyradiculoneuropathy 30.1 IL17A IL10 IFNG
29 lymphopenia 30.0 TYK2 IL6 IL18 IL10 IFNG
30 thymoma 30.0 TNF IL6 IL17A IFNA1
31 xerophthalmia 30.0 TRIM21 TNFSF13B RO60 CD40LG
32 purpura 30.0 TNFSF13B TNF IL6 IL10 IFNG CD40LG
33 sialadenitis 30.0 TRIM21 TNFSF13B TNF RO60
34 neutropenia 30.0 TNF IL6 IL1B IL10 IFNG IFNA1
35 amyloidosis 30.0 TNF IL6 IL1B CD40LG
36 basal cell carcinoma 30.0 TNF KRT15 IL6 IL1B IL10
37 myasthenia gravis 29.9 TNFSF13B TNF IL10 IFNG CD40LG
38 juvenile rheumatoid arthritis 29.9 TNF IL6 IL1B IL18 IL10 IFNG
39 keratoconjunctivitis 29.9 TRIM21 TNF IL6 IL17A IFNG
40 pericarditis 29.9 TNF IL6 IL1B IFNG CD40LG
41 allergic hypersensitivity disease 29.9 TNF SELE IL17A IL10 IFNG
42 sarcoidosis 1 29.9 TNF IL1B IL18 IFNG CXCR3 CD40LG
43 vasculitis 29.9 TNFSF13B TNF SELE IL6 IL17A IL10
44 autoimmune hepatitis 29.9 TNF IL6 IL10 IFNA1 CD40LG
45 aggressive periodontitis 29.8 TNF IL6 IL1B IL17A IL10
46 spondylitis 29.8 TNF IL6 IL17A IL10 IFNG
47 endocarditis 29.7 TNF IL6 IL17A IL10 IFNG
48 myositis 29.7 TRIM21 TNF IL6 IL1B IL17A IFNG
49 cerebrovascular disease 29.7 TREX1 TNF SELE IL6 CD40LG
50 peripheral nervous system disease 29.6 TNF IL6 IL1B IL17A IL10 IFNG

Graphical network of the top 20 diseases related to Cutaneous Lupus Erythematosus:



Diseases related to Cutaneous Lupus Erythematosus

Symptoms & Phenotypes for Cutaneous Lupus Erythematosus

UMLS symptoms related to Cutaneous Lupus Erythematosus:


pruritus, exanthema

GenomeRNAi Phenotypes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 CD40LG IL10 IL17A IL18 IL1B TNF
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 IL10 IL17A IL18 IL1B MX1 TNF

MGI Mouse Phenotypes related to Cutaneous Lupus Erythematosus:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.33 CD40LG CXCR3 IFNG IL10 IL17A IL18
2 homeostasis/metabolism MP:0005376 10.27 CD40LG CXCR3 IFNG IL10 IL17A IL18
3 immune system MP:0005387 10.25 CD40LG CXCR3 IFNG IL10 IL17A IL18
4 cardiovascular system MP:0005385 10.16 CD40LG CXCR3 IFNG IL10 IL18 IL1B
5 digestive/alimentary MP:0005381 10.03 IFNG IL10 IL17A IL18 IL6 KRT15
6 integument MP:0010771 10.03 CD40LG IFNG IL10 IL17A IL18 IL1B
7 mortality/aging MP:0010768 10.03 CD40LG CXCR3 IFNG IL10 IL17A IL18
8 renal/urinary system MP:0005367 9.56 CD40LG CXCR3 IFNG IL17A IL6 RO60
9 respiratory system MP:0005388 9.23 CXCR3 IFNG IL10 IL17A IL6 SELE

Drugs & Therapeutics for Cutaneous Lupus Erythematosus

Drugs for Cutaneous Lupus Erythematosus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 4 356547-88-1 10451420 5957
2 Immunosuppressive Agents Phase 4
3 Immunologic Factors Phase 4
4
Hydroxychloroquine Approved Phase 3 118-42-3 3652
5 Anti-Infective Agents Phase 3
6 Antiparasitic Agents Phase 3
7 Antiprotozoal Agents Phase 3
8 Antimalarials Phase 3
9 Sunscreening Agents Phase 3
10 Protective Agents Phase 3
11 Radiation-Protective Agents Phase 3
12
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
13
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
14
Dimethyl fumarate Approved, Investigational Phase 2 624-49-7 5271565 637568
15
Norflurane Approved, Experimental Phase 2 811-97-2
16
Etanercept Approved, Investigational Phase 2 185243-69-0
17
Apremilast Approved, Investigational Phase 1, Phase 2 608141-41-9 11561674
18
Tofacitinib Approved, Investigational Phase 1, Phase 2 477600-75-2
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Abatacept Approved Phase 2 332348-12-6 10237
21
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
23 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
24
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
25
Mycophenolic acid Approved Phase 2 24280-93-1 446541
26
Alitretinoin Approved, Investigational Phase 2 5300-03-8 449171 444795
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
29
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
30
Vitamin D3 Approved, Nutraceutical Phase 2 67-97-0 5280795 6221
31
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
32
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
33 Vitamin B Complex Phase 2
34 Lipid Regulating Agents Phase 2
35 Vitamin B3 Phase 2
36 Nicotinic Acids Phase 2
37 Vasodilator Agents Phase 2
38 Folate Phase 2
39 Vitamin B9 Phase 2
40 Hypolipidemic Agents Phase 2
41 Antimetabolites Phase 2
42 Analgesics, Non-Narcotic Phase 2
43 Analgesics Phase 2
44 Anti-Inflammatory Agents Phase 2
45 Anti-Inflammatory Agents, Non-Steroidal Phase 2
46 Gastrointestinal Agents Phase 2
47 Phosphodiesterase 5 Inhibitors Phase 1, Phase 2
48 Protein Kinase Inhibitors Phase 1, Phase 2
49 Antirheumatic Agents Phase 2
50 Methylprednisolone Acetate Phase 2

Interventional clinical trials:

(show all 44)
# Name Status NCT ID Phase Drugs
1 Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy Unknown status NCT02270970 Phase 4
2 Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial Unknown status NCT03178188 Phase 2, Phase 3
3 A Randomized, Double Blind, Baseline Controlled Study Using Placebo as Reference for Assessing the Efficacy and Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus in the Presence of Active Lupus Erythematosus Specific Skin Lesion Completed NCT01551069 Phase 3 hydroxychloroquine (Z0188);Placebo
4 Photoprotective Effects of the RV 2457C Sunscreen Milk in Photoinduced Cutaneous Lupus Erythematosus Completed NCT00470912 Phase 3 sunscreen RV 2547C
5 A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE) Unknown status NCT01845740 Phase 1, Phase 2 milatuzumab;Placebo
6 An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus Unknown status NCT03260166 Phase 2 nicotinamide
7 A Multi-center, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy and Tolerability of KRP203 in Patients With Active Subacute Cutaneous Lupus Erythematosus Completed NCT01294774 Phase 2 KRP203 - 1.2mg;Placebo to KRP203 - 1.2 mg
8 A Phase 2, Pilot, Multicenter, Sequential, Ascending Dose Study to Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus Completed NCT01300208 Phase 2 CC-11050
9 A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Completed NCT03134222 Phase 2 Lanraplenib;Filgotinib;Lanraplenib placebo;Filgotinib placebo
10 The Efficacy of Topical Tacrolimus in the Treatment of Cutaneous Lupus Erythematosus - a Multi-Center-Trial Completed NCT00317681 Phase 2 Tacrolimus ointment
11 A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations Completed NCT02847598 Phase 2 BIIB059;Placebo
12 Efficacy and Safety of Fumaric Acid Esters (Fumaderm®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Mono-Centre, Open-Label, Prospective Pilot Study Completed NCT01352988 Phase 2 Fumaric acid esters
13 Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus Completed NCT00523588 Phase 2
14 A Single Arm, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus Completed NCT02656082 Phase 2 Etanercept
15 Clinical and Immune-modulating Effects of CC-10004 in Discoid Lupus Erythematosus Completed NCT00708916 Phase 1, Phase 2 CC-10004
16 A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 45 With Moderate to Severe Skin Involvement Due to Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
17 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study) Active, not recruiting NCT02270957 Phase 2
18 A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Guselkumab in Subjects With Active Lupus Nephritis Not yet recruiting NCT04376827 Phase 2 Guselkumab Dose 1;Placebo;Guselkumab Dose 2;Standard-of-care treatment
19 Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study Terminated NCT01407679 Phase 2 Alitretinoin
20 Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus Terminated NCT01498406 Phase 2
21 A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients Completed NCT02927457 Phase 1 GSK2646264 1%;Placebo
22 A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus Completed NCT01702740 Phase 1 1 mg/kg CNTO 136;4 mg/kg CNTO 136;10 mg/kg CNTO 136;Placebo
23 A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy Completed NCT02652546 Phase 1 Assess Safety;Effect of drug on viral load;Effect of drug on T-cell count;Effect of drug on inflammatory biomarkers
24 A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis Active, not recruiting NCT03817424 Phase 1 VIB7734;Placebo
25 A Randomized, Subject And Investigator-Blinded (Sponsor-Open), Placebo-Controlled Study To Evaluate The Safety, Tolerability, And Preliminary Efficacy Of Multiple Ascending Doses Of PD- 0360324 In Subjects With Active Cutaneous Lupus Erythematosus (CLE) Terminated NCT01470313 Phase 1 PD-0360324;Placebo
26 A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08) Terminated NCT02428309 Phase 1
27 A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus Terminated NCT01389895 Phase 1 AMG 557;AMG 557 Placebo
28 European Society of Cutaneous Lupus Erythematosus Unknown status NCT00420121
29 Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers Completed NCT02034344
30 Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus Completed NCT01923415
31 Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus Completed NCT01629784
32 Interdisciplinary Study Group of Lupus Erythematosus Completed NCT00420173
33 Investigation of the Efficacy of Different Sunscreens in Patients With Photosensitive Cutaneous Lupus Erythematosus Completed NCT01146444
34 A Pilot Study to Evaluate Using Tape Harvesting to Collect Ribonucleic Acid From the Upper Epidermis of Healthy Volunteers and Subjects With Discoid Lupus, Subjects With Subacute Cutaneous Lupus, and Subjects With Atopic Dermatitis Completed NCT02125695
35 Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus Completed NCT00633945 Lenalidomide
36 Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus Completed NCT01841619 Early Phase 1 IVIg
37 Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus Recruiting NCT01510067
38 Low-dose UVA1 Radiation in Cutaneous Lupus Patients Recruiting NCT01776190
39 Duke Lupus Registry Recruiting NCT00512694
40 Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus : to a Form of Lichen Planus-like Lupus Erythematosus ? Active, not recruiting NCT04356014
41 Molecular Studies on Cutaneous Lupus Active, not recruiting NCT01266915
42 Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid Terminated NCT01559155
43 A Comparative Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone Terminated NCT03639857 Topical corticosteroid
44 Evaluation of the Therapeutic Effect and Local Tolerability of Elidel® Cream 1% (Pimecrolimus) in Chronic Discoid Lupus Erythematosus (dLE) or Subacute Cutaneous Lupus Erythematosus (scLE) Withdrawn NCT00222183 Elidel (pimecrolimus)

Search NIH Clinical Center for Cutaneous Lupus Erythematosus

Genetic Tests for Cutaneous Lupus Erythematosus

Anatomical Context for Cutaneous Lupus Erythematosus

MalaCards organs/tissues related to Cutaneous Lupus Erythematosus:

40
Skin, T Cells, Lung, Heart, Kidney, Testes, Breast

Publications for Cutaneous Lupus Erythematosus

Articles related to Cutaneous Lupus Erythematosus:

(show top 50) (show all 1594)
# Title Authors PMID Year
1
CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease. 54 61
18280341 2008
2
Elevated soluble E-selectin in cutaneous lupus erythematosus. 54 61
10599337 1999
3
Relationship between heat shock protein induction and the binding of antibodies to the extractable nuclear antigens on cultured human keratinocytes. 54 61
8345220 1993
4
Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. 61 54
2132545 1990
5
The influence of interferon on healthy and diseased skin. 61
30527631 2020
6
Generalized facial pigmentation: An uncommon presentation of cutaneous lupus erythematosus. 61
32461382 2020
7
Childhood subacute cutaneous lupus erythematosus associated with transaminitis. 61
31850540 2020
8
Three cases of subacute cutaneous lupus erythematosus associated with malignancy: a late paraneoplastic phenomenon. 61
31944366 2020
9
Pigmented linear discoid lupus erythematosus following the lines of Blaschko: A retrospective study of a Chinese series. 61
32270767 2020
10
A secondary discoid lupus erythematosus induced by scald of edible oil: An illustration of Koebner phenomenon. 61
31660688 2020
11
Subacute cutaneous lupus erythematosus with positive anti-Ro antibodies following palbociclib and letrozole treatment: A case report and literature review. 61
32119141 2020
12
Cutaneous lupus erythematosus patients in a high-epidemic COVID-19 area, Bergamo, Italy. 61
32506525 2020
13
Scarring alopecia in chronic cutaneous lupus erythematosus with neutrophils: A new scenario with therapeutic connotations. 61
32483922 2020
14
Subacute cutaneous lupus erythematosus with melanocyte elimination induced by pembrolizumab. 61
32173880 2020
15
Chronic cutaneous lupus erythematosus (discoid lupus) induced by palbociclib. 61
31724158 2020
16
Influenza vaccine-associated cutaneous lupus erythematosus. 61
31675446 2020
17
Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain. 61
32539659 2020
18
A clinical population pharmacokinetic/pharmacodynamic model for BIIB059, a monoclonal antibody for the treatment of systemic and cutaneous lupus erythematosus. 61
32335844 2020
19
Successful treatment of refractory lupus erythematosus profundus with the interleukin-6 antagonist tocilizumab: a case report. 61
32192399 2020
20
Treatment of cutaneous lupus erythematosus: current approaches and future strategies. 61
32141953 2020
21
Autoimmune disease development before and after cutaneous lupus erythematosus diagnosis. 61
31647114 2020
22
Worsening skin damage in patients with cutaneous lupus erythematosus may predict development of systemic lupus erythematosus. 61
32407740 2020
23
Secukinumab-induced subacute cutaneous lupus erythematosus. 61
32291870 2020
24
Staphylococcus aureus Colonization Is Increased on Lupus Skin Lesions and Is Promoted by IFN-Mediated Barrier Disruption. 61
31877319 2020
25
Lichen planus follicularis tumidus: immunotyping of the inflammatory infiltrate with focus on plasmacytoid dendritic cells. 61
32458476 2020
26
Cutaneous Lupus Erythematosus: Progress and Challenges. 61
32248318 2020
27
Successful ustekinumab treatment in a patient with psoriasis and subacute cutaneous lupus erythematosus. 61
31957866 2020
28
Tumid Lupus Erythematosus and Systemic Lupus Erythematosus: A Report on Their Rare Coexistence. 61
32377493 2020
29
A Case of Papulonodular Mucinosis in a Patient With Systemic Lupus Erythematosus. 61
31567136 2020
30
Exclusion of cutaneous lupus erythematosus subtypes from the 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: comment on the article by Aringer et al. 61
32336046 2020
31
Ovoid palatal patch: a clue to anti-TIF1γ dermatomyositis. 61
32332045 2020
32
Discoid Lupus Erythematosus Lesions Associated with Systemic Fluorouracil Agents: A Case Report and Review. 61
32467803 2020
33
Familial chilblain lupus due to a novel mutation in TREX1 associated with Aicardi-Goutie'res syndrome. 61
32293470 2020
34
Non-bullous neutrophilic lupus erythematosus-Muted bullous disease? 61
32317541 2020
35
Long-lasting successful treatment of a donkey with cutaneous lupus erythematous with methotrexate. 61
32293082 2020
36
Cutaneous effects of antihypertensive drugs. 61
31195782 2020
37
Comparison of Cutaneous Lupus Erythematosus in Indigenous and Non-Indigenous Patients at a Regional Centre in Australia. 61
32255506 2020
38
Cutaneous Lupus Erythematosus: Current and Future Pathogenesis-Directed Therapies. 61
32226339 2020
39
Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report. 61
29625815 2020
40
Analysis of clinical characteristics of drug-induced cutaneous lupus erythematosus in men. 61
32151631 2020
41
An update on the use of hydroxychloroquine in cutaneous lupus erythematosus: A systematic review. 61
31306730 2020
42
[Resistant and progressive cutaneous lupus erythematosus treated with belimumab: A retrospective monocentric study]. 61
31980188 2020
43
A Case of Linear Cutaneous Lupus Erythematosus in a 55-Year-Old Woman. 61
32173718 2020
44
Complete Remission of Hypertrophic Discoid Cutaneous Lupus Erythematosus After Treatment of Chronic Hepatitis C With Direct-Acting Antivirals. 61
32129794 2020
45
Inflammatory and T Helper 17/ Regulatory T Cells Related Cytokines Balance in Cutaneous Lupus Erythematosus (CLE). 61
32245325 2020
46
Acute Generalized Cutaneous Lupus Erythematosus Repeatedly Mistaken for Cellulitis. 61
32190497 2020
47
Cutaneous lupus erythematosus and its association with systemic lupus erythematosus: A nationwide population-based cohort study in Korea. 61
31773752 2020
48
A Missense Variant Affecting the C-Terminal Tail of UNC93B1 in Dogs with Exfoliative Cutaneous Lupus Erythematosus (ECLE). 61
32028618 2020
49
Metastatic prostate cancer presenting as subacute cutaneous lupus erythematosus. 61
31407804 2020
50
Association between oral lesions and disease activity in lupus erythematosus. 61
31566809 2020

Variations for Cutaneous Lupus Erythematosus

Expression for Cutaneous Lupus Erythematosus

Search GEO for disease gene expression data for Cutaneous Lupus Erythematosus.

Pathways for Cutaneous Lupus Erythematosus

Pathways related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show top 50) (show all 79)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 TYK2 TRIM21 TREX1 TNFSF13B TNF MX1
2
Show member pathways
13.88 TNFSF13B TNF IL6 IL1B IL18 IL17A
3
Show member pathways
13.77 TYK2 TNFSF13B TNF IL6 IL1B IL18
4
Show member pathways
13.62 TYK2 TNFSF13B TNF IL6 IL1B IL18
5
Show member pathways
13.49 TNFSF13B TNF IL6 IL1B IL18 IL17A
6
Show member pathways
13.4 TNFSF13B TNF IL6 IL1B IL18 IL17A
7
Show member pathways
13.24 TYK2 TRIM21 TNFSF13B TNF MX1 IRF7
8
Show member pathways
13.17 TYK2 TNF MX1 IRF7 IRF5 IL6
9
Show member pathways
13 TYK2 TNF IRF7 IL6 IL1B IFNA1
10
Show member pathways
12.96 TNFSF13B TNF IL6 IL1B IL17A IL10
11
Show member pathways
12.91 TYK2 TNF MX1 IRF7 IL6 IL1B
12 12.9 TYK2 TNF IRF7 IL6 IL1B IFNG
13
Show member pathways
12.81 TNF IRF7 IL6 IL1B IL18 IFNA1
14
Show member pathways
12.76 TNFSF13B TNF IL6 IL1B CD40LG
15
Show member pathways
12.74 TYK2 TNF IL6 IL1B IL18 IL17A
16
Show member pathways
12.73 TYK2 TNF IL6 IL1B IL18 IL17A
17
Show member pathways
12.72 TNF IL6 IL1B IL17A IL10 IFNG
18
Show member pathways
12.7 TNF IL18 IL10 IFNG CD40LG
19
Show member pathways
12.67 TRIM21 TREX1 IRF7 IL6 IL1B IL18
20
Show member pathways
12.65 TYK2 TRIM21 MX1 IRF7 IRF5 IFNG
21
Show member pathways
12.52 TYK2 IL6 IL10 IFNG IFNA1
22
Show member pathways
12.43 TNF IL6 IL1B IL17A IFNG
23
Show member pathways
12.43 TNF IL6 IL18 IL10 CXCR3
24 12.41 TYK2 TNFSF13B TNF IRF7 IRF5 IL1B
25
Show member pathways
12.39 TYK2 TNF IL1B IL10 IFNG CD40LG
26
Show member pathways
12.38 TNF IL6 IL1B IFNG
27 12.36 TNF IL6 IL1B IL18
28 12.36 TYK2 TNF IRF7 IL6 IL1B IL18
29 12.34 TNF IL6 IL1B IL18 IL10 IFNG
30 12.33 TNF IL6 IL1B IL18
31
Show member pathways
12.31 TYK2 TNF IL1B IFNG IFNA1
32
Show member pathways
12.28 TNF IL6 IL1B IL10
33
Show member pathways
12.25 TNF IL6 IL1B IFNG
34 12.24 TNF IL6 IL1B IL10
35 12.17 TNF SELE IL1B IFNG
36 12.14 TNF IL6 IL1B IL18 IL10
37 12.14 TNFSF13B TNF IL6 IL1B IFNG
38 12.13 TYK2 TNF IL1B IFNG
39 12.1 TYK2 TNF IL6 IL1B IL18 IL17A
40 12.08 TNF IL6 IL10 IFNG
41 12.08 IRF7 IRF5 IL6 IL1B IFNG
42
Show member pathways
12.07 TYK2 IL1B IL18 IFNG
43 12.06 TNF SELE IL6 IL1B
44 12.06 TNF IL6 IL1B IL10 IFNG
45 12.03 TNFSF13B TNF IL1B CD40LG
46 12.01 TNF SELE IL6 IL1B
47
Show member pathways
12 TYK2 IL6 IL1B IL17A IFNG
48
Show member pathways
12 TYK2 TNF IL6 IL1B IL18 IL17A
49 11.97 TNFSF13B TNF IL6 IL1B IL18 IL17A
50 11.96 TYK2 IL6 IFNG IFNA1

GO Terms for Cutaneous Lupus Erythematosus

Cellular components related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 TNFSF13B TNF IL6 IL1B IL18 IL17A
2 extracellular space GO:0005615 9.36 TNFSF13B TNF SELE IL6 IL1B IL18

Biological processes related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.36 TNFSF13B MX1 IL6 IL1B IL18 IL10
2 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TNF IRF7 IRF5 IL6 IL1B IL18
3 positive regulation of gene expression GO:0010628 10.14 TNF IL6 IL1B IL18 IFNG
4 regulation of gene expression GO:0010468 10.08 TRIM21 TREX1 RO60 IRF7 IL10
5 cellular response to lipopolysaccharide GO:0071222 10.01 TNF IL6 IL1B IL10
6 response to virus GO:0009615 9.94 TNF MX1 IRF7 IFNG
7 B cell differentiation GO:0030183 9.91 IL10 IFNA1 CD40LG
8 regulation of insulin secretion GO:0050796 9.91 TNF IL1B IFNG
9 positive regulation of inflammatory response GO:0050729 9.91 TNF IL1B IL18 IFNG
10 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.91 TRIM21 TNF IL6 IL1B IL18 CD40LG
11 cellular response to organic cyclic compound GO:0071407 9.9 TNF IL1B IL18
12 response to glucocorticoid GO:0051384 9.9 TNF IL6 IL10
13 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.9 TNF IL1B IL18
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF IL6 IL18
15 positive regulation of interleukin-6 production GO:0032755 9.89 TNF IL6 IL1B
16 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 TNF IL6 IL18 IFNG
17 interferon-gamma-mediated signaling pathway GO:0060333 9.88 TRIM21 IRF7 IRF5 IFNG
18 positive regulation of phagocytosis GO:0050766 9.87 TNF IL1B IFNG
19 defense response to virus GO:0051607 9.87 TREX1 MX1 IRF7 IRF5 IL6 IFNG
20 interleukin-12-mediated signaling pathway GO:0035722 9.86 TYK2 IL10 IFNG
21 positive regulation of interferon-gamma production GO:0032729 9.86 TNF IL1B IL18
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 TNF IL1B IFNG
23 B cell proliferation GO:0042100 9.85 IL10 IFNA1 CD40LG
24 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TRIM21 TNF IL6 IL1B IL10
25 lipopolysaccharide-mediated signaling pathway GO:0031663 9.84 TNF IL1B IL18
26 positive regulation of T cell proliferation GO:0042102 9.84 TNFSF13B IL6 IL1B CD40LG
27 positive regulation of cytokine secretion GO:0050715 9.83 TNF IL10 IFNG
28 positive regulation of JAK-STAT cascade GO:0046427 9.83 TNF IL6 IL10
29 negative regulation of neurogenesis GO:0050768 9.81 TNF IL6 IL1B
30 humoral immune response GO:0006959 9.81 TNF IL6 IFNG IFNA1
31 inflammatory response GO:0006954 9.81 TREX1 TNF SELE IL6 IL1B IL18
32 positive regulation of interleukin-12 production GO:0032735 9.8 IRF5 IFNG CD40LG
33 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.79 TNF IL6 IL17A
34 positive regulation of osteoclast differentiation GO:0045672 9.79 TNF IL17A IFNG
35 positive regulation of interleukin-6 secretion GO:2000778 9.78 TNF IL1B IL17A IFNG
36 positive regulation of glial cell proliferation GO:0060252 9.77 TNF IL6 IL1B
37 astrocyte activation GO:0048143 9.77 TNF IL1B IFNG
38 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.74 IL1B IL18
39 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 TNF IL1B IFNG
41 positive regulation of MHC class II biosynthetic process GO:0045348 9.73 IL10 IFNG
42 negative regulation of lipid storage GO:0010888 9.73 TNF IL6
43 interleukin-6 production GO:0032635 9.73 IL1B IL18
44 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.73 TNF IL1B IL10
45 type I interferon signaling pathway GO:0060337 9.73 TYK2 TREX1 MX1 IRF7 IRF5 IFNA1
46 regulation of establishment of endothelial barrier GO:1903140 9.72 TNF IL1B
47 endothelial cell apoptotic process GO:0072577 9.72 TNF IL10
48 response to peptidoglycan GO:0032494 9.72 IRF5 IL6
49 regulation of type I interferon production GO:0032479 9.72 TRIM21 TREX1 IRF7
50 type 2 immune response GO:0042092 9.71 IL18 IL10

Molecular functions related to Cutaneous Lupus Erythematosus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNFSF13B TNF IL6 IL1B IL18 IL17A
2 tumor necrosis factor receptor binding GO:0005164 9.13 TNFSF13B TNF CD40LG

Sources for Cutaneous Lupus Erythematosus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....